Literature DB >> 18377821

Randomized trial of bevacizumab in advanced renal cell carcinoma.

Ronald M Bukowski.   

Abstract

Entities:  

Year:  2008        PMID： 18377821     DOI： 10.1007/s11912-008-0016-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  4 in total

Review 1.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

2.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

Authors:  John D Hainsworth; Jeffrey A Sosman; David R Spigel; Donna L Edwards; Cara Baughman; Anthony Greco
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

3.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

Authors:  Ronald M Bukowski; Fairooz F Kabbinavar; Robert A Figlin; Keith Flaherty; Sandy Srinivas; Ulka Vaishampayan; Harry A Drabkin; Janice Dutcher; Sarah Ryba; Qi Xia; Frank A Scappaticci; David McDermott
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

4.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245
  4 in total
  2 in total

1.  Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer.

Authors:  Ryo Morita; Kazuhiro Sato; Mariko Nakano; Hajime Miura; Hidesato Odaka; Kiyoshi Nobori; Toshimitsu Kosaka; Masaaki Sano; Hiroyuki Watanabe; Takanobu Shioya; Hiroshi Ito
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-17       Impact factor: 4.553

Review 2.  Renal toxicity of targeted therapies.

Authors:  Ronan J Kelly; Bertrand Billemont; Olivier Rixe
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.